What are the appropriate mood‑stabilizing medications for managing both acute mania and bipolar depression?

Mood Stabilizers for Bipolar Disorder: Mania and Depression

For acute mania, start with lithium, quetiapine, divalproex, or a second-generation antipsychotic (aripiprazole, risperidone, asenapine, paliperidone, or cariprazine) as monotherapy or in combination; for acute bipolar depression, use quetiapine monotherapy, lurasidone plus lithium or divalproex, lithium alone, lamotrigine monotherapy, or adjunctive lamotrigine—never use antidepressants as monotherapy. 1

Acute Mania Management

First-Line Monotherapy Options

• Lithium remains the gold-standard mood stabilizer with FDA approval for patients ≥12 years, providing both antimanic efficacy and long-term suicide prevention. 1
• Divalproex (valproate) is particularly effective for mixed or dysphoric mania and serves as the primary alternative when lithium is contraindicated. 1, 2
• Second-generation antipsychotics approved as monotherapy include quetiapine, aripiprazole, asenapine, paliperidone, risperidone, and cariprazine. 1, 2
• Quetiapine offers a favorable side-effect profile among atypicals despite common sedation; start at 25 mg orally every 12 hours. 1
• Aripiprazole at 10 mg daily balances efficacy with lower risk of extrapyramidal symptoms and weight gain compared to higher doses or other agents. 1

Combination Therapy Strategy

• Adding an atypical antipsychotic to lithium is superior to switching agents when acute mania develops in patients already on lithium monotherapy. 3, 4
• Olanzapine plus lithium demonstrates high efficacy with strong evidence for acute manic episodes. 3
• Aripiprazole holds FDA approval for acute mania and is effective as adjunctive therapy to lithium. 3
• Combination therapy shows significant improvement within the first week (standardized mean difference -0.25) and maintains superiority through 6 weeks (odds ratio 1.59). 4
• Maintain the combination for at least 4 weeks after acute stabilization to achieve lower relapse rates. 3

Agents to Avoid in Acute Mania

• Never use antidepressants during manic or mixed episodes—they destabilize mood and can precipitate further mania. 1, 3
• Gabapentin and topiramate lack efficacy for acute mania. 3
• Benzodiazepines should not serve as primary therapy, though short-term use (e.g., lorazepam 1 mg) may address acute agitation or insomnia. 1, 3
• Avoid first-generation antipsychotics when possible due to higher extrapyramidal symptom risk; haloperidol may be used only when second-generation agents are unavailable. 1

Acute Bipolar Depression Management

First-Line Options

• Quetiapine monotherapy is a first-line choice for bipolar depression with established efficacy. 1, 2, 5
• Lurasidone combined with lithium or divalproex is FDA-approved and highly effective. 1, 2
• Lithium monotherapy shows modest but meaningful efficacy for depressive episodes. 1, 2
• Lamotrigine monotherapy is FDA-approved for maintenance and provides particular protection against depressive recurrence, though it requires slow titration (serious rash risk ~0.1% with proper dosing). 1
• Adjunctive lamotrigine added to an existing mood stabilizer provides modest benefit (standardized mean difference -0.30). 1
• Olanzapine-fluoxetine combination is FDA-approved for bipolar depression and addresses both depressive and anxiety symptoms. 1

Critical Antidepressant Safety Rule

• Antidepressants must never be used as monotherapy in bipolar disorder—patients must already be receiving at least one mood stabilizer (preferably valproate when lithium cannot be used). 1, 3
• Bupropion, SSRIs, and venlafaxine are preferred antidepressants when needed for comorbid depression or anxiety. 6
• Taper antidepressants 2–6 months after remission to minimize switch risk. 6
• Recent meta-analysis found no antidepressant significantly increased switch risk versus placebo, though venlafaxine showed the highest (non-significant) risk estimate (RR 4.53). 7

Lamotrigine-Specific Considerations

• Lamotrigine is ineffective for acute mania—use lithium, valproate, or a second-generation antipsychotic for manic episodes. 1
• Limited efficacy as monotherapy for preventing manic/hypomanic episodes, but highly effective at preventing depressive recurrence. 1
• When co-prescribed with enzyme inducers (carbamazepine, phenytoin, phenobarbital), use accelerated titration: 50 mg daily weeks 1–2,100 mg daily weeks 3–4,200 mg daily from week 5, with maintenance 200–400 mg/day. 1
• Never accelerate titration without enzyme inducers—this increases rash risk dramatically (adjusted OR ≈8.15). 1

Maintenance Treatment

Long-Term Mood Stabilization

• Lithium is FDA-approved for maintenance therapy (age ≥12 years) and remains the preferred long-term agent, protecting against both manic and depressive recurrences while reducing suicidal behavior. 1, 2
• Lamotrigine is FDA-approved for maintenance and complements lithium's antimanic effect by providing superior protection against depressive recurrence. 1, 2
• Continue maintenance pharmacotherapy for at least 2 years after the most recent bipolar episode to lower relapse risk. 1, 3
• The medication regimen that stabilizes the acute phase should generally be maintained for 12–24 months, with some patients requiring lifelong therapy. 1, 3
• First-line maintenance options include lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole as monotherapy or combination treatments. 2, 8

Discontinuation Protocol

• Taper prophylactic mood stabilizers gradually with close monitoring for relapse during tapering. 1
• Assess mood stability weekly, then bi-weekly for 3 months after discontinuation. 1

Critical Monitoring Requirements

Lithium Monitoring

• Baseline labs: complete blood count, thyroid function (TSH, free T4), urinalysis, blood urea nitrogen, creatinine, serum calcium, and pregnancy test in females. 1
• Ongoing monitoring every 3–6 months: serum lithium concentration, renal function, thyroid function, urinalysis, and calcium. 1

Atypical Antipsychotic Monitoring

• Baseline assessment: body-mass index, waist circumference, blood pressure, fasting glucose, and fasting lipid panel. 1
• BMI monitoring: monthly for the first 3 months, then quarterly thereafter to detect metabolic syndrome (affects ~37% of bipolar patients). 1
• Blood pressure, fasting glucose, and lipids: reassess at 3 months and annually. 1
• Assess for extrapyramidal side effects at each visit. 1
• Monitor for treatment-emergent suicidality, especially during medication initiation or changes. 1

Valproate Monitoring

• Baseline: liver function tests, complete blood count, and pregnancy test in females. 1
• Ongoing every 3–6 months: serum drug levels, hepatic enzymes, and hematologic indices. 1

Common Pitfalls to Avoid

• Metabolic monitoring must not be overlooked with atypical antipsychotics—weight gain and metabolic syndrome are common, particularly with olanzapine and risperidone. 1, 3
• Do not use benzodiazepines as monotherapy for anxiety in bipolar disorder due to disinhibition risk in younger patients and addiction potential. 1
• Allow 6–8 weeks at therapeutic doses before deeming a mood stabilizer ineffective for acute episodes. 1
• Carbamazepine serves as a third-line mood stabilizer when both lithium and valproate are unsuitable, with less robust evidence. 1

Adjunctive Psychosocial Treatment

• Routine psychoeducation should accompany all pharmacologic regimens to improve treatment adherence and clinical outcomes. 1
• For children and adolescents, family-focused treatment, child- and family-focused CBT, and psychoeducational psychotherapy increase mood-symptom improvement and recovery rates when added to pharmacotherapy. 1